Total Payments
$1,216
2024 Payments
$122.10
Companies
17
Transactions
62
Medicare Patients
11,150
Medicare Billing
$6.2M
Payment Breakdown by Category
Food & Beverage$1,216 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,216 | 62 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $399.19 | 16 | $0 (2020) |
| UCB, Inc. | $135.36 | 7 | $0 (2023) |
| AbbVie Inc. | $127.01 | 8 | $0 (2023) |
| Amgen Inc. | $88.05 | 5 | $0 (2024) |
| Janssen Biotech, Inc. | $80.03 | 4 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $72.27 | 4 | $0 (2024) |
| Fresenius Kabi USA, LLC | $44.20 | 2 | $0 (2024) |
| Ultragenyx Pharmaceutical Inc. | $42.07 | 2 | $0 (2022) |
| Sandoz Inc. | $39.94 | 2 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $33.99 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $122.10 | 6 | Novartis Pharmaceuticals Corporation ($25.85) |
| 2023 | $255.23 | 13 | AbbVie Inc. ($41.36) |
| 2022 | $24.06 | 1 | Ultragenyx Pharmaceutical Inc. ($24.06) |
| 2021 | $128.86 | 8 | AbbVie Inc. ($34.59) |
| 2020 | $75.87 | 4 | Horizon Therapeutics plc ($26.70) |
| 2019 | $215.07 | 7 | Genentech USA, Inc. ($167.49) |
| 2018 | $192.67 | 11 | Genentech USA, Inc. ($66.38) |
| 2017 | $202.03 | 12 | Genentech USA, Inc. ($140.38) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/28/2024 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Food and Beverage | In-kind items and services | $22.99 | General |
| Category: Biosimilars | ||||||
| 08/21/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Inflammation | ||||||
| 07/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.26 | General |
| Category: Immunology | ||||||
| 04/18/2024 | Sandoz Inc. | HYRIMOZ (Biological) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Immunology | ||||||
| 04/10/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: Immunology | ||||||
| 01/24/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $25.85 | General |
| Category: Dermatology | ||||||
| 11/08/2023 | Sandoz Inc. | HYRIMOZ (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: IMMUNOLOGY | ||||||
| 09/06/2023 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological), TREMFYA, REMICADE | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Immunology | ||||||
| 08/24/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: Immunology | ||||||
| 08/16/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: Immunology | ||||||
| 07/26/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: IMMUNOLOGY | ||||||
| 07/19/2023 | Organon LLC | HADLIMA (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: ADALIMUMAB-BWWD | ||||||
| 05/04/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: IMMUNOLOGY | ||||||
| 04/05/2023 | PFIZER INC. | XELJANZ (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 03/22/2023 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $22.67 | General |
| Category: Immunology | ||||||
| 03/21/2023 | Fresenius Kabi USA, LLC | IDACIO (Biological) | Food and Beverage | In-kind items and services | $21.21 | General |
| Category: Biosimilars | ||||||
| 02/16/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: Immunology | ||||||
| 02/01/2023 | Lilly USA, LLC | TALTZ (Drug), OLUMIANT | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: Immunology | ||||||
| 01/10/2023 | Amgen Inc. | Enbrel (Biological), TAVNEOS | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: Inflammation | ||||||
| 10/03/2022 | Ultragenyx Pharmaceutical Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: XLH Metabolic Bone Disorder | ||||||
| 11/10/2021 | Ultragenyx Pharmaceutical Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $18.01 | General |
| Category: XLH Metabolic Bone Disorder | ||||||
| 11/05/2021 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.05 | General |
| Category: IMMUNOLOGY | ||||||
| 09/21/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV | Food and Beverage | In-kind items and services | $15.68 | General |
| 08/17/2021 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Immunology | ||||||
| 08/13/2021 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.05 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 2,643 | 74,141 | $4.6M | $1.6M |
| 2022 | 50 | 3,035 | 64,863 | $4.2M | $1.5M |
| 2021 | 48 | 3,090 | 83,242 | $4.4M | $1.8M |
| 2020 | 40 | 2,382 | 40,898 | $3.0M | $1.3M |
Total Patients
11,150
Total Services
263,144
Medicare Billing
$6.2M
Procedure Codes
188
All Medicare Procedures & Services
188 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 57 | 25,725 | $2.1M | $865,545 | 42.1% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 39 | 7,110 | $981,180 | $184,684 | 18.8% |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | Office | 2023 | 25 | 14,377 | $646,965 | $151,240 | 23.4% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 14 | 16,320 | $118,320 | $76,566 | 64.7% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2023 | 23 | 2,390 | $212,355 | $74,986 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 232 | 759 | $113,850 | $68,271 | 60.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 144 | 664 | $219,120 | $65,018 | 29.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 20 | 1,920 | $57,600 | $35,421 | 61.5% |
| 86481 | Tuberculosis test, enumeration of t-cells | Office | 2023 | 80 | 80 | $10,000 | $7,840 | 78.4% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 34 | 131 | $15,720 | $7,138 | 45.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 40 | 52 | $9,360 | $6,467 | 69.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 67 | 94 | $8,930 | $5,518 | 61.8% |
| 80076 | Liver function blood test panel | Office | 2023 | 213 | 689 | $41,340 | $5,488 | 13.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 205 | 684 | $14,364 | $5,176 | 36.0% |
| 82565 | Blood creatinine level | Office | 2023 | 232 | 730 | $15,330 | $3,645 | 23.8% |
| 82306 | Vitamin d-3 level | Office | 2023 | 90 | 117 | $7,371 | $3,365 | 45.7% |
| 86140 | Measurement c-reactive protein for detection of infection or inflammation | Office | 2023 | 197 | 659 | $29,655 | $3,328 | 11.2% |
| 86235 | Measurement of antibody for assessment of autoimmune disorder, any method | Office | 2023 | 24 | 176 | $6,160 | $3,093 | 50.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 171 | 368 | $2,576 | $2,524 | 98.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $4,560 | $2,401 | 52.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $3,145 | $2,101 | 66.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $8,645 | $1,877 | 21.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 33 | 71 | $3,550 | $1,501 | 42.3% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 40 | 40 | $6,000 | $1,415 | 23.6% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 33 | 35 | $2,975 | $1,375 | 46.2% |
About Gregory Borstad
Gregory Borstad is a Hospitalist healthcare provider based in Wilmington, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/18/2005. The National Provider Identifier (NPI) number assigned to this provider is 1528057056.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Gregory Borstad has received a total of $1,216 in payments from pharmaceutical and medical device companies, with $122.10 received in 2024. These payments were reported across 62 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($1,216).
As a Medicare-enrolled provider, Borstad has provided services to 11,150 Medicare beneficiaries, totaling 263,144 services with total Medicare billing of $6.2M. Data is available for 4 years (2020–2023), covering 188 distinct procedure/service records.
Ad
Practice Information
- Specialty Hospitalist
- Other Specialties Rheumatology
- Location Wilmington, NC
- Active Since 10/18/2005
- Last Updated 02/08/2024
- Taxonomy Code 208M00000X
- Entity Type Individual
- NPI Number 1528057056
Products in Payments
- Rituxan (Biological) $207.31
- Actemra (Biological) $191.88
- Cimzia (Drug) $135.36
- RINVOQ (Biological) $75.95
- Enbrel (Biological) $60.42
- COSENTYX (Biological) $46.42
- SIMPONI ARIA (Biological) $45.27
- IDACIO (Biological) $44.20
- Crysvita (Drug) $42.07
- TREMFYA (Drug) $34.76
- Humira (Biological) $33.21
- TALTZ (Drug) $32.36
- KRYSTEXXA (Biological) $26.70
- COSENTYX (Drug) $25.85
- HYRIMOZ (Biological) $23.48
- ORENCIA (Biological) $22.67
- XELJANZ (Drug) $18.70
- Rinvoq (Biological) $17.85
- HADLIMA (Drug) $17.70
- Zilretta (Drug) $16.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hospitalist Doctors in Wilmington
Kevin Cannon, M.d, M.D
Hospitalist — Payments: $57,844
Hospitalist $57,844
Dr. Ricki Carroll, M.d, M.D
Hospitalist — Payments: $23,101
Hospitalist $23,101
Dr. Hassan Issa, Md, MD
Hospitalist — Payments: $4,746
Hospitalist $4,746
Jennifer Pagliei, Md, MD
Hospitalist — Payments: $1,447
Hospitalist $1,447
Eric Hansberry, Md, MD
Hospitalist — Payments: $1,379
Hospitalist $1,379
Dr. Oyakhire Ofori, M.d, M.D
Hospitalist — Payments: $1,206
Hospitalist $1,206